Phase 1 Neonatal Unit
The Phase 1 neonatal unit is a highly specialized clinical research environment embedded within a tertiary-level Neonatal Intensive Care Unit (NICU), specifically designed to conduct early-phase clinical studies in neonates. The unit operates in full compliance with stringent regulatory, ethical, and safety standards, enabling the conduct of first-in-neonate and early safety and pharmacokinetic studies. The unit is fully equipped for continuous physiological monitoring, including heart rate, respiratory rate, oxygen saturation, blood pressure, and body temperature. Advanced life-support systems, precision low-volume infusion pumps, and immediate access to neonatal resuscitation resources are available at all times. Clinical care and research activities are delivered by a dedicated multidisciplinary team comprising neonatologists, research-trained neonatal nurses, clinical pharmacologists, and research coordinators. All personnel have extensive experience in the administration and monitoring of opioid analgesics in neonates, including fentanyl. Two Phase 1 clinical studies – Fentanyl TH and EVENEW – are currently being conducted within this specialized Phase 1 neonatal unit located in a tertiary NICU.
Both studies are early-phase clinical investigations designed to primarily assess safety and tolerability, with additional evaluation of pharmacokinetic and pharmacodynamic parameters, in carefully selected neonatal populations under strictly controlled clinical conditions. For the Fentanyl TH study, the Phase 1 neonatal unit provides:
- precise dose administration under controlled conditions;
- close monitoring of pharmacodynamic effects, including analgesia, sedation, and respiratory function;
- serial blood sampling using minimal-volume techniques for pharmacokinetic analyses;
- continuous surveillance, documentation, and reporting of adverse events and serious adverse events.
Strict inclusion and exclusion criteria are applied, and written informed consent is obtained from parents or legal guardians prior to study participation. Safety oversight includes predefined stopping rules, real-time adverse event reporting, and regular review by an independent safety monitoring body. The Phase 1 neonatal unit ensures that study participation does not compromise standard clinical care and that the safety, well-being, and rights of enrolled neonates are prioritized at all times.